Gain Therapeutics Inc (GANX)
$1.05
Performance
- $1.00$1.08$1.05
4.76%
Downside
Day's Volatility :7.41%
Upside
2.78%
- $0.89$5.33$1.05
15.24%
Downside
52 Weeks Volatility :83.3%
Upside
80.3%
Returns
| Period | Gain Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -52.27% | 0.0% |
6 Months | -77.17% | 0.0% |
1 Year | -71.23% | 0.0% |
3 Years | -86.71% | -22.3% |
Highlights
Market Capitalization | 26.8M |
Book Value | $0.47 |
Earnings Per Share (EPS) | -1.31 |
Wall Street Target Price | 7.4 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -72.96% |
Return On Equity TTM | -188.83% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -7.7M |
EBITDA | -21.8M |
Diluted Eps TTM | -1.31 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.05 |
EPS Estimate Next Year | -0.89 |
EPS Estimate Current Quarter | -0.2 |
EPS Estimate Next Quarter | -0.2 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 604.76%
Technicals Summary
Sell
Neutral
Buy
Gain Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Gain Therapeutics Inc | 10.24% | -77.17% | -71.23% | -86.71% | -90.62% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Gain Therapeutics Inc | NA | NA | NA | -1.05 | -1.89 | -0.73 | NA | 0.47 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Gain Therapeutics Inc | Buy | $26.8M | -90.62% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Gain Therapeutics Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 108.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 155.9%
Institutional Holdings
Alyeska Investment Group, L.P.
1.76%HOHIMER WEALTH MANAGEMENT, LLC
1.29%Royal Bank of Canada
0.97%Geode Capital Management, LLC
0.69%Vanguard Group Inc
0.57%CM Management, LLC
0.35%
Company Information
gain therapeutics is a preclinical stage biotech company specializing in the discovery of new drugs for orphan diseases. the company targets inborn errors of metabolism; a group of rare diseases of genetic origin with a high unmet medical need. gain therapeutics is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – see-tx. the gain therapeutics team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.
Organization | Gain Therapeutics Inc |
Employees | 29 |
CEO | Dr. Khalid Islam Ph.D. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$1.05
-3.23%
Keyarch Acquisition Corp
$1.05
-3.23%
Connexa Sports Technologies Inc
$1.05
-3.23%
Us Value Etf
$1.05
-3.23%
First Wave Biopharma Inc
$1.05
-3.23%
Global X Msci Next Emerging
$1.05
-3.23%
Fat Projects Acquisition Corp
$1.05
-3.23%
Capital Link Global Fintech
$1.05
-3.23%
Applied Uv Inc
$1.05
-3.23%